Chih Chang, MD
Endocrinology, Diabetes & Metabolism · Sellersburg, INNPI 1104835958
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 454 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,031 and has fallen 63.8% since, to $736 in 2025.
Across 454 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Amgen$757
- Abbott$455
- Bayer$379
- plus $4K from 40 others
What the payments were for
- Travel & lodging$6527%
- Food & beverage$8,70592%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$938
- FREESTYLE LIBRE 3$211
- TWIIST$150
- Omnipod$141
- NEXLIZET$125
- NEXLETOL$125
- Kerendia$120
- Ozempic$120
- DEXCOM G7 GSS (161)$119
- Prolia$113
- PRALUENT$111
How this compares
$9,477 in reported general payments places this provider in the 80th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 570 | $713,741 |
| OzempicSemaglutide | 486 | $645,235 |
| TrulicityDulaglutide | 240 | $318,255 |
| JardianceEmpagliflozin | 236 | $288,546 |
| FarxigaDapagliflozin Propanediol | 249 | $265,325 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 101 | $191,177 |
| Tresiba Flextouch U-100Insulin Degludec | 146 | $117,559 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $97,906 |
| JanuviaSitagliptin Phosphate | 63 | $82,761 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 74 | $76,772 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 102 | $66,162 |
| RybelsusSemaglutide | 31 | $65,196 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $61,293 |
| ForteoTeriparatide | 14 | $59,793 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $57,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Baqsimi | $1,025 | $1,122,765870 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $1,096 | $731,319545 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $338 | $351,229296 claims |
| AstraZenecaFarxiga | $195 | $265,325249 claims |
| MerckJanuvia, Janumet Xr | $314 | $159,532137 claims |
| Johnson & JohnsonInvokana | $158 | $42,12635 claims |
| BayerKerendia | $379 | $38,39634 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $325 | $35,06944 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Sellersburg
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.